We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
-11.22%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$960M
AUM Growth
-$305M
(-24%)
Cap. Flow
-$75.3M
Cap. Flow
% of AUM
-7.85%
Top 10 Holdings %
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3
Top Buys
| 1 |
ABVX
Abivax
ABVX
|
+$70.9M |
| 2 |
Disc Medicine
IRON
|
+$16.5M |
| 3 |
EyePoint Inc
EYPT
|
+$12.9M |
| 4 |
Savara
SVRA
|
+$10.5M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.06M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$61.2M |
| 2 |
Geron
GERN
|
+$57.4M |
| 3 |
Structure Therapeutics
GPCR
|
+$37.1M |
| 4 |
ATXS
Astria Therapeutics
ATXS
|
+$24.6M |
| 5 |
KALV
KalVista Pharmaceuticals
KALV
|
+$13.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$6.14B
| $116M | 12.08% |
3,670,206
+100,000
| +3% | +$3.47M |
|
2
Dyne Therapeutics
DYN
$3.73B
| $93.5M | 9.75% |
2,650,150
| – | – |
|
|
ABVX
3
Abivax
ABVX
$11.7B
| $80.1M | 8.34% |
6,056,596
+4,956,596
| +451% | +$70.9M |
|
|
SLN
4
Silence Therapeutics
SLN
$491M
| $62.6M | 6.53% |
3,295,350
| – | – |
|
5
Cogent Biosciences
COGT
$6.43B
| $58.7M | 6.12% |
6,964,375
+750,000
| +12% | +$5.69M |
|
|
6
Savara
SVRA
$1.14B
| $49.8M | 5.19% |
12,362,205
+2,362,205
| +24% | +$10.5M |
|
7
Madrigal Pharmaceuticals
MDGL
$12.4B
| $41.8M | 4.36% |
149,283
| – | – |
|
8
Edgewise Therapeutics
EWTX
$4.1B
| $40.9M | 4.27% |
2,272,728
| – | – |
|
9
Keros Therapeutics
KROS
$206M
| $40.2M | 4.19% |
879,344
| – | – |
|
10
Mineralys Therapeutics
MLYS
$2.34B
| $37.3M | 3.88% |
3,185,185
| – | – |
|
11
Ocular Therapeutix
OCUL
$1.94B
| $36.4M | 3.79% |
5,319,148
| – | – |
|
12
Tyra Biosciences
TYRA
$1.87B
| $31.8M | 3.31% |
1,989,103
| – | – |
|
13
Kura Oncology
KURA
$958M
| $29.3M | 3.06% |
1,423,642
| – | – |
|
|
14
Structure Therapeutics
GPCR
$3.3B
| $27.3M | 2.84% |
694,547
-903,874
| -57% | -$37.1M |
|
|
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
| $26.1M | 2.72% |
2,890,816
+850,000
| +42% | +$8.06M |
|
|
ATXS
16
DELISTED
Astria Therapeutics
ATXS
| $25.1M | 2.62% |
2,761,861
-2,517,067
| -48% | -$24.6M |
|
|
CMPS
17
Compass Pathways
CMPS
$1.66B
| $23.3M | 2.43% |
3,858,000
| – | – |
|
|
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
| $22.4M | 2.34% |
550,000
| – | – |
|
|
19
Disc Medicine
IRON
$2.83B
| $21.9M | 2.29% |
+486,957
| New | +$16.5M |
|
|
TRML
20
DELISTED
Tourmaline Bio
TRML
| $19M | 1.98% |
1,477,593
| – | – |
|
21
Tarsus Pharmaceuticals
TARS
$2.54B
| $15.1M | 1.58% |
556,317
-237,512
| -30% | -$7.99M |
|
|
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
| $13.8M | 1.44% |
2,008,340
| – | – |
|
23
VistaGen Therapeutics
VTGN
$9.78M
| $9.31M | 0.97% |
2,676,580
| – | – |
|
24
Entrada Therapeutics
TRDA
$261M
| $8.34M | 0.87% |
584,955
| – | – |
|
|
25
EyePoint Inc
EYPT
$1.09B
| $8.02M | 0.84% |
+922,335
| New | +$12.9M |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC